{
    "clinical_study": {
        "@rank": "156468", 
        "arm_group": {
            "arm_group_label": "RX-5902", 
            "arm_group_type": "Experimental", 
            "description": "RX-5902 will be taken on Days 1, 8, and 15 followed by a week of rest on Day 22 of a 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the maximum tolerated dose of RX-5902 in subjects\n      with advanced or metastatic solid tumors."
        }, 
        "brief_title": "RX-5902 Treatment of Subjects With Solid Tumors", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumor", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated\n      for up to 6 cycles of therapy. RX-5902 will be administered orally once a week for 3 weeks\n      followed by 1 week of rest in each cycle. All subjects will be followed for at least 30 days\n      after the last dose of study agent for safety."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female who are 18 yrs or older\n\n          -  Histologically confirmed solid tumor malignancy that are refractory, intolerant, or\n             ineligible to receive approved standard therapies\n\n          -  Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors\n             (RECIST)\n\n          -  Life expectancy of at least 3 months\n\n          -  Able to swallow capsules\n\n          -  Provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Primary brain tumor or active brain metastasis\n\n          -  Not recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or\n             neuropathy) associated with previous cancer therapies\n\n          -  Any other cancer treatments within 2 weeks of planned study treatment\n\n          -  History of any medical or psychiatric condition or addictive disorder, or lab\n             abnormality that in the opinion of the investigator, may increase risks or may\n             interfere with study participation or interpretation of study results\n\n          -  History of clinically significant GI bleed, intestinal obstruction, or GI perforation\n             within 6 months of study dose\n\n          -  Uncontrolled diabetes\n\n          -  History of long QT syndrome or clinically significant cardiac arrhythmias (except\n             stable atrial fibrillation)\n\n          -  Myocardial infarction within 6 months of study dose\n\n          -  Active infection requiring IV antibiotics within 2 weeks of study dose\n\n          -  History of Hepatitis B, C, or HIV\n\n          -  Taking any sensitive substrates, strong inducers or inhibitors of cytochrome P450\n             enzymes, transporters, and conjugating enzymes\n\n          -  Receiving other investigational agents or not yet completed 30 days since completion\n             of an investigational study\n\n          -  Pregnant, planning a pregnancy, or breast feeding\n\n          -  Male or female not willing to use adequate contraceptive precautions during the study\n             period. Females must either be surgically sterile, post-menopausal for 12 months, or\n             use a contraceptive approved by sponsor.\n\n          -  Unwilling or unable to provide written informed consent, comply with study\n             requirements, or be available for follow-up assessments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003092", 
            "org_study_id": "RX-5902-P1-01"
        }, 
        "intervention": {
            "arm_group_label": "RX-5902", 
            "description": "escalating doses (mg)", 
            "intervention_name": "RX-5902", 
            "intervention_type": "Drug", 
            "other_name": "Supinoxin\u2122"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "solid tumor", 
            "Rexahn", 
            "Phase 1"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Rexahn Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Rexahn Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "Rexahn Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors", 
        "other_outcome": {
            "measure": "phosphorylated P68 by IHC", 
            "safety_issue": "No", 
            "time_frame": "baseline and 8 weeks"
        }, 
        "overall_contact": {
            "email": "trank@rexahn.com", 
            "last_name": "Kathy Tran", 
            "phone": "240-268-5300", 
            "phone_ext": "365"
        }, 
        "overall_official": {
            "affiliation": "Rexahn Pharmaceuticals, Inc.", 
            "last_name": "Christine Peterson, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of dose limiting toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "after 4 weeks of treatment with RX-5902"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of RX-5902", 
                "safety_issue": "Yes", 
                "time_frame": "predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hrs after the first dose"
            }, 
            {
                "measure": "Changes in tumor size mm", 
                "safety_issue": "No", 
                "time_frame": "baseline and 24 weeks"
            }
        ], 
        "source": "Rexahn Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rexahn Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}